SLC12A2 and Parkinson disease: Bumetanide blocks NKCC1 activity at low doses to restore physiological intracellular Cl– levels and GABAergic inhibition, and has been successful in treating core symptoms in epilepsy, various models of autism, schizophrenia, pain, PD, Down syndrome, and brain trauma (Ben-Ari, 2017).